Zag Bio
Targeting the thymus to treat autoimmunity
Cambridge, United States · Founded 2022 · $80.0M raised
- Headquarters
- Cambridge, Massachusetts
- Employees
- 11–50
- Founded
- 2022
- Business Model
- B2B
- Website
- zagbio.com
- Total Funding
- $80.0M
- Last Round
- $80.0M Series AOct 2025
- Rounds
- 1
About
Biotech company developing thymus-targeted bifunctional antibody therapies to restore immune tolerance and treat autoimmune diseases, starting with Type 1 diabetes.
Summary
Zag Bio is a Biotech company based in Cambridge, United States, founded in 2022. It has raised $80.0M in total across 1 round, most recently a $80.0M Series A round in Oct 2025. Investors include Polaris Partners, JDRF T1D Fund and AbbVie Ventures.
Tech & App Stack
3 technologies & apps tracked
Create a free account — 10 credits a month to unlock the full tech & app stack, funding history, and valuations.
Sign up to view the funding chart
Create a free account — you'll get 10 credits a month to unlock funding history, valuations, and tech stacks.
Funding History
Oct 2025
Investors
Similar Companies
Biotech advancing cellular rejuvenation programming to restore cell health and reverse disease.
AI-first drug discovery company using AlphaFold-derived models to design therapeutics and acceler...
Asymchem provides R&D and one-stop production services to the world's top pharmaceutical companies.
Alphabet-backed biotechnology company researching biology of aging and developing interventions t...
BridgeBio makes targeted treatments for genetic diseases.
Developer of engineered cells as medicines to treat diseases by repairing or replacing cells for ...